Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 31, 2025. The filing serves to disclose the issuance of a press release regarding financial results for the fourth quarter and full year ended December 31, 2024, as well as recent corporate developments.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced in a press release (Exhibit 99.1) but does not reproduce the financial data within the body of the 8-K.
Material Changes
No specific material changes in financial condition or operations are detailed in this text. The filing references the announcement of Q4 and full-year 2024 results but does not quantify variances versus prior periods.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release containing management commentary and corporate developments. The text explicitly states that the information furnished under Item 2.02 and Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific forward-looking guidance or risk factors are enumerated in this excerpt.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2025) for actual Q4 and full-year 2024 financial figures.
- Verify the specific details of "recent corporate developments" mentioned in the press release.
- Confirm the company's cash runway and burn rate, as these are not stated in the 8-K text.
- Check for any updates on clinical trial progress or regulatory milestones referenced in the omitted press release.